How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide.
Kastritis
Efstathios
E
Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece.
Dimopoulos
Meletios
M
D000970:Antineoplastic Agents / Q000009:adverse effects*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy*; D013792:Thalidomide / Q000009:adverse effects* / Q000031:analogs & derivatives*; D020246:Venous Thrombosis / Q000517:prevention & control*
D000970:Antineoplastic Agents; D006495:Heparin, Low-Molecular-Weight; D013792:Thalidomide; D000077269:Lenalidomide